Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page's revision label updated from v3.5.3 to v3.5.4, indicating a new release of the site's backend or content management. This change does not alter trial information shown to users.
    Difference
    0.0%
    Check dated 2026-05-16T09:25:53.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The page’s footer revision label was updated from **v3.5.2** to **v3.5.3**, indicating a site/version refresh rather than a change to the study record.
    Difference
    0.0%
    Check dated 2026-04-25T05:21:56.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T23:57:32.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Revision: v3.5.0 deployed.
    Difference
    0.0%
    Check dated 2026-03-20T01:22:14.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3; no user-visible changes to the study page.
    Difference
    0.0%
    Check dated 2026-03-12T21:00:05.000Z thumbnail image
  9. Check
    107 days ago
    Change Detected
    Summary
    A minor page revision was applied, moving from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-12T01:41:51.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.